Eleven U.S. stocks with buybacks amid market pessimism

The screen highlights U.S. companies with market caps above US$5B that combine FCF yield above 5%, sales growth above 10%, EV/EBITDA below 10x, and aggressive buybacks, suggesting undervalued fundamentals despite weak share performance. The Trade Desk stands out with a 61.5% one-year decline but 16.2% sales growth and a 148.3% BBY/FCFY ratio; Universal Health Services and EPAM also screen well on growth and valuation. The article is primarily a contrarian stock-selection piece rather than a company-specific catalyst, so direct market impact is limited.

Analysis

The common thread across these names is not just cheapness, but management signaling. Aggressive repurchases after a sharp drawdown usually matter most when the business still has operating leverage left to defend — that can create a reflexive setup where lower share counts support EPS while sentiment remains anchored to old peak multiples. The second-order effect is that these companies can re-rate faster than the broader market expects once buybacks absorb incremental supply and buy-side positioning is still underweight.

TTD is the cleanest contrarian expression, but also the most fragile. The market is effectively pricing a prolonged competitive or demand reset, so the key question is whether repurchases are merely offsetting employee dilution or are truly absorbing meaningful float; if the latter, the marginal seller has already been exhausted and a sharp squeeze is possible over the next 3-6 months. Still, ad-tech is prone to narrative whiplash, so the downside case is that buybacks are a confidence signal rather than proof of durability if revenue decelerates again.

UHS screens as the most defensive value compounder: low multiple, positive momentum, and capital return support create a better margin of safety than the other two names. The hidden risk is political/regulatory rather than competitive — hospital reimbursement or labor cost pressure can lag the headline fundamentals by several quarters, so the stock can keep working until a policy shock resets margins. EPAM is the highest-quality cyclical recovery, but it is more dependent on IT spend stabilization than on internal capital allocation; if enterprise software budgets re-accelerate, multiple expansion can happen quickly, but if macro stays soft, the buyback just slows the bleed.

Key Decisions for Investors

• Go long a basket of TTD/UHS/EPAM on post-earnings weakness over the next 1-2 quarters; target 15-25% upside on a 6-12 month horizon if buyback activity persists and fundamentals do not deteriorate.
• Buy TTD as the highest-beta contrarian recovery trade, but size smaller; use a 3-6 month window and pair with a short in a more expensive ad-tech/marketing software name if available, because the upside is fastest if sentiment snaps back.
• Prefer UHS as the core long for a lower-volatility expression; hold 6-12 months and expect mid-single-digit downside protection from capital returns, with rerating potential if healthcare reimbursement headlines remain benign.
• Use EPAM as a cyclical quality trade only if enterprise IT spending data stabilizes; enter on any analyst-driven downdraft, with a 6-9 month target tied to margin normalization and multiple expansion rather than pure earnings growth.
• Avoid naked shorting these names into buyback-heavy periods; if expressing skepticism, hedge via a sector basket or market hedge instead, since repurchases can create a sharp squeeze when float supply is thin.